Loading...
Presenters at this year's meeting of the IASLC World Conference on Lung Cancer, held in Vienna, Austria, August 6–9, reported the latest research in lung cancer. NEJM Group covered the meeting, with guidance from NEJM Journal Watch Oncology and Hematology Associate Editor Jyoti D. Patel, MD, FASCO. Here are some highlights of that coverage.
The addition of nivolumab to neoadjuvant chemotherapy improved overall survival (OS) in patients with resectable stage IIIA–IIIB non–small-cell lung cancer (NSCLC), according to the phase 2 NADIM II trial.
In the open-label, randomized trial, 57 patients were assigned to receive neoadjuvant nivolumab (360 mg) plus paclit…